Methods and kits for monitoring membranous nephropathy
The present invention relates to the protein THSD7A (Thrombospondin, Type I, Domain Containing 7A) as a biomarker autoantigen in membranous nephropathy, particularly idiopathic membranous nephropathy. The invention provides diagnostic, prognostic and monitoring methods for membranous nephropathy in a patient based on the detection of autoantibodies recognizing the THSD7A protein (anti-THSD7A autoantibodies) and associated kits. The invention also provides diagnostic methods and kits based on the detection of the THSD7A level. The invention further provides therapeutic methods for membranous nephropathy.
1. An in vitro method for assessing the effectiveness of a treatment for membranous nephropathy in a patient, said method comprising:
(i) determining at a first time point a level of an antibody against a Thrombospondin, Type I, Domain Containing 7A (THSD7A) polypeptide in a sample obtained from said patient at said first time point,
(ii) determining at a second time point a level of an antibody against the THSD7A polypeptide in a sample obtained from said patient at said second time point, and
(iii) comparing the levels of the autoantibodies of the two time points,
wherein:
a decrease in the level of anti-THSD7A autoantibodies in the second time point compared to the first time point indicates that the treatment is effective, and/or an increase in the level of anti-THSD7A autoantibodies in the second time point compared to the first time point indicates that the treatment is not effective.
2. The method according to claim 1 , wherein said method is performed with a device coated with the THSD7A polypeptide or a fragment thereof.
3. The method according to claim 1 , wherein said membranous nephropathy is idiopathic membranous nephropathy.
4. A kit for diagnosing and/or prognosing membranous nephropathy in a patient, said kit comprising:
a THSD7A polypeptide or an antibody-binding fragment thereof,
a reagent for detection of an antigen-antibody complex formed between the THSD7A polypeptide or an antibody-binding fragment thereof and an autoantibody directed against THSD7A present in the biological sample, and
a PLA2R1 polypeptide or an antibody-binding fragment thereof.